Depomed Names Bukofzer Chief Medical & Scientific Officer

Stan Bukofzer has been named senior vice president, chief medical and scientific officer of Newark, CA-based Depomed (NASDAQ: [[ticker:DEPO]]). Bukofzer was most recently chief medical officer of Ocera Therapeutics, which was acquired by Mallinkrodt (NYSE: [[ticker:MNK]]) last year. He succeeds Santosh Vetticaden, who Depomed says decided not to relocate to the company’s new headquarters in Illinois. Vetticaden will remain with the company through the end of the month to help with the transition. Depomed develops and markets pain and neurology drugs.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan